Study finds weekly GLP-1 added to therapy cut heavy drinking more than therapy alone

A study reported on April 30, 2026 found that adding a weekly GLP-1 medicine to cognitive behavioral therapy reduced heavy drinking more than cognitive behavioral therapy alone ^[1][2]. No GLP-1 medicine is approved in the United States to treat alcohol use disorder, and the work remains investigational ^[1][2].

The results were summarized in the FDA approval timelines that track semaglutide products, which list the finding under that date ^[1][2]. Details beyond the direction of the result have not been reported. The specific weekly GLP-1 used has not been named, so it is not known whether it was semaglutide (sold as Ozempic, Wegovy and Rybelsus) or tirzepatide (sold as Mounjaro and Zepbound), or another molecule. The dose, the number of participants, how long they were followed, and how much heavy drinking fell in each group have not been reported. Whether the results have appeared in a peer-reviewed journal has not been disclosed.

Where GLP-1 medicines stand with the FDA

Six semaglutide products are approved in the US under different brand names and forms. Ozempic injection was first approved on December 5, 2017 for type 2 diabetes, and its approved uses now also include reducing the risk of major cardiovascular events and of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease ^[2]. Rybelsus tablets were first approved on September 20, 2019 for type 2 diabetes; that product was rebranded as Ozempic tablets on January 30, 2026 ^[2]. Wegovy injection was first approved on June 4, 2021 for weight management, later adding cardiovascular risk reduction and, on August 15, 2025, accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis ^[1]. Wegovy tablets were approved on December 22, 2025 ^[1][2], and a higher-dose Wegovy HD injection (7.2 mg) was approved on March 19, 2026 ^[1].

None of those labels list alcohol use disorder ^[1][2]. The Wegovy label also states that using it with another semaglutide product or any other GLP-1 receptor agonist is not recommended ^[1].

Both Ozempic and Wegovy carry a boxed warning for an increased risk of thyroid C-cell tumors. Warnings and precautions include acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, increased heart rate, suicidal behavior and ideation, and pulmonary aspiration during general anesthesia or deep sedation ^[1][2]. Commonly reported side effects at rates of 5 percent or more include nausea, vomiting, diarrhea, constipation and abdominal pain ^[1][2]. The sources do not describe how the study drug interacted with alcohol, and no new safety information about alcohol use has been reported.

Why it matters for patients

Many people already take a weekly GLP-1 for weight management, type 2 diabetes, cardiovascular risk reduction or MASH ^[1][2]. This finding does not change what those medicines are cleared for. A prescription specifically for heavy drinking or alcohol use disorder would fall outside FDA-approved labeling, which is a decision made between a patient and a prescriber, not something the label supports ^[1][2].

Because the trial's size, drug, dose and effect size have not been reported, there is no way to judge from the current information how large the added benefit was or how it would compare with other approaches to heavy drinking. The result points to a research direction, not to an approved treatment option. Anyone taking a GLP-1 for an approved use has no new reason from this report to change how they take it.

What happens next

No next steps have been reported. Neither approval timeline lists a follow-up trial, a journal publication or an FDA submission tied to this research; the later entries on the Wegovy timeline cover obesity and mobility data presented in May 2026, not alcohol outcomes ^[1][2]. The name of the study drug, the full results and any regulatory path for treating alcohol use disorder with a GLP-1 remain undisclosed.